分子靶向治疗新药在临床转移性肾癌治疗中的应用

Molecular targeted therapy in the treatment of metastatic renal cell carcinoma

肾细胞癌(RCC)对化疗、放疗以及激素治疗均不敏感。细胞因子治疗是其主要方法,但有效率低且毒副作用明显,尤其转移性肾癌(mRCC)患者很少能从中获益。近些年,随着肿瘤分子生物学的不断发展,分子靶向治疗成为mRCC治疗新策略。本文重点针对血管内皮生长因子通路和雷帕霉素靶蛋白通路综述几种新型分子靶向治疗药物的临床应用。

Renal cell carcinoma（RCC） is not sensitive to chemotherapy,radiation therapy or hormone therapy.Cytokine therapy is the main treatment to RCC,but it has lower efficacy and obvious adverse reactions.Moreover,patients with metastatic renal cell carcinoma（mRCC） are rarely able to benefit from cytokine therapy.Recent years,as the development of tumor molecular biology,molecular targeted therapy becomes a new treatment strategy for mRCC.This review focuses on the clinical application of some new molecular targeted therapies with vascular endothelial growth factor and mammalian target of rapamycin pathway.